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A new tendency in the development of dry powder inhalers
(DPIs) is the design of carrier-basedmicrocomposites particle
size (3-5 µm) as pulmonary drug delivery systems involving
different carriers and adjuvants. The adjuvants are applied in
small amounts in the microcomposites in order to promote
physicochemical stability, wettability, dispersibility and
aerodynamic properties.
A new possibility in drug formulation is applying Meloxicam
in a salt form (Meloxicam Potassium (MXP)) to develop DPI.
Using its salt form could be a novel application, trough
alternative routes, because it has never used before in the
drug therapy.
Meloxicam Potassium (MXP) purchased from EGIS Ltd.,
Budapest, Hungary, PVA 3-88 from ISP Customer Service
GmBH, Cologne, Germany, Leucin (LEU) from
Hungaropharma, Budapest, Hungary.
The heated solutions containing MXP, , were
spray-driedwith aBüchiMini Dryer B-191 (Fig. 1).
The particle size distribution of themicrocomposites was also
estimated by laser diffraction (Malvern Mastersizer Scirocco
2000, Malvern Instruments Ltd., Worcestershire, UK). The
morphology of the microcomposites was examined by SEM
(Hitachi S4700,Hitachi Scientific Ltd., Tokyo, Japan).
Evaluation of the structural analysis usingDSCandXRPD,we
can conclude that the rawMXP is crystalline and additives are
semi-crystalline materials. The crystalline form of MXP turned
to amorphous character in the presence of PVA(crystallization
inhibitor effect). When LEU was applied the characteristic
peaks of MXP on the XRPD patterns and its melting on the
DSCcurveswere detected(Figs. 5-7).
Our aims were therefore to apply aqueous solution of MXP
containing additives in different concentrations (using one-
step green technology), which help to improve the
aerodynamic properties of the product.
LEU and/or PVA
Andersen Cascade Impactor (ACI) (Copley Scientific Ltd.,
Nottingham, UK) is used for measuring the mass distribution
of pharmaceutical aerosols via the aerodynamic diameter
using 60Lmin flow rate. The products were filled into hard
gelatine capsules (size 3). The inhaler device applied was a
plasticRS01 (Plastiape, Italy).
XRPD was carried out in order to determine the crystalline
formand crystallinity of the producedmaterials. Sampleswere
measured with a Bruker D8 Advance diffractometer (Bruker
AXS GmbH, Karlsruhe, Germany). Thermoanalitical
measurements were also applied (Mettler Toledo, Stare
programW9,Mettler Inc. SwerzenbachSwitzerland)
The particle sizes of the samples satisfied the pharmacopoeial
requirements, the ave .
Moreover, the particle size distribution of MXP and many
products was heterodispers only MXPspd, MXP-PVA0.1 and
MXP-LEU2-PVA0.1 resulted homogenous distribution (Fig. 2-
3 and Table 1). The crystal morphology is a critical parameter
for DPI development, because the particle shape affects the
aerodynamic behaviour and thus lung deposition. The effect of
spray-drying procedure on the morphology of particles was
determinative. The nearly spherical form of the
microcomposites could be advantageous for suitable
pulmonary depositions.
Fig. 4 and Table 2 show the amounts of drug deposited on the
throat, on stages 7 and on the filter of ACI, expressed as
percentages of the total amount of powder recovered. All of
the products exhibited favourable aerolisation characteristics,
these powder particles impacting on stages 2-5. Bigger
concentration of PVA without LEU resulted only poor
aerodynamic character, because of the sticky of the particles.
But PVA in small concentration shown an excellent result. The
MMAD values were around 3 , and 46-66 % FPF could be
acceptable for pulmonary application and presented better
result comparewith themarketedDPI products.
-1
rage size was between 2.5-4.5 μm
μm
The goal of our study was to find the optimized co-spray drying
parameters, sample compositions for the preparation of DPI
form of a novel MXP salt monohydrate. The MXP-PVA0.1 and
MXP-LEU2-PVA0.1 could be an innovative products which
may be considered suitable for scaled-up processes and
pulmonary application. It is a novel possibility in anti-
inflammatory treatment and for the mono- and combination
therapy of cancer, pulmonary fibrosis and pain.
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Figure 2. Particle size distribution
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Figure 7. XRPD patterns of the samples
Figure 3. Morphology of the products
Figure 6. DSC curves of the samples
Figure 4. Aerodynamic-pattern
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Figure 5. Structure of the raw samples
Introduction, aim
Experimental methods
Results
Figure 1. Compositions and preparation procedure
Co-spray-drying procedure:
Inlet temperature: 140 °C
Feed rate: 005 %
Aspirator air: 600 L/min
Aspirator rate: 75 %
FPD: Fine Particle Dose
FPF: Fine Particle Fraction
MMAD: Median Mass Aerodynamic Diameter
Samples MXP PVA LEU
MXPSPD 1 - -
MXP-LEU1 1 - 1
MXP-LEU2 1 - 2
MXP-PVA0.1 1 0.1 -
MXP-PVA0.25 1 0.25 -
MXP-LEU1-
PVA0.25
1 0.25 1
MXP-LEU2-
PVA0.1
1 0.1 2
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